These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 24238173)

  • 1. Scleromyxedema: a novel therapeutic approach.
    El-Darouti MA; Hegazy RA; Fawzy MM; Mahmoud SB; Dorgham DA
    J Am Acad Dermatol; 2013 Dec; 69(6):1062-6. PubMed ID: 24238173
    [No Abstract]   [Full Text] [Related]  

  • 2. Scleromyxedema presenting with neurologic symptoms: a case report and review of the literature.
    Marshall K; Klepeiss SA; Ioffreda MD; Helm KF
    Cutis; 2010 Mar; 85(3):137-40. PubMed ID: 20408512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of scleromyxedema with intravenous immunoglobulin.
    Roque Diamantino Fde E; Lopes João AM; Clemente Fidalgo AI; Taveira Lobo Mde L
    Eur J Dermatol; 2010; 20(6):861-2. PubMed ID: 20956104
    [No Abstract]   [Full Text] [Related]  

  • 4. Scleromyxedema with monoclonal gammopathy and neurological involvement: recovery from coma after plasmapheresis?
    do Prado AD; Schmoeller D; Bisi MC; Piovesan DM; Dias FS; Staub HL
    Int J Dermatol; 2012 Aug; 51(8):1013-5. PubMed ID: 21671910
    [No Abstract]   [Full Text] [Related]  

  • 5. Thalidomide and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema.
    Bos R; de Waal EG; Kuiper H; Hazenberg BP; Vellenga E
    Rheumatology (Oxford); 2011 Oct; 50(10):1925-6. PubMed ID: 21719421
    [No Abstract]   [Full Text] [Related]  

  • 6. Self-healing juvenile cutaneous mucinosis manifesting with subcutaneous nodules.
    Nanda A; Selim MK; Al-Sabah H; Singhal V; Kapila K
    Indian J Dermatol Venereol Leprol; 2010; 76(2):198-9. PubMed ID: 20228561
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful therapy of scleromyxoedema Arndt-Gottron with low-dose intravenous immunoglobulin.
    Körber A; Franckson T; Grabbe S; Dissemond J
    J Eur Acad Dermatol Venereol; 2007 Apr; 21(4):553-4. PubMed ID: 17373996
    [No Abstract]   [Full Text] [Related]  

  • 8. Scleromyxedema.
    Heymann WR
    J Am Acad Dermatol; 2007 Nov; 57(5):890-1. PubMed ID: 17939940
    [No Abstract]   [Full Text] [Related]  

  • 9. Widespread skin thickening.
    Shimol JB; Vyas N; Evans J
    Cutis; 2019 Dec; 104(6):E15-E17. PubMed ID: 31939938
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical characteristics, outcome of scleromyxoedema: a retrospective multicentre study].
    Le Moigne M; Mazereeuw-Hautier J; Bonnetblanc JM; Astudillo L; D'Incan M; Bessis D; Thomas L; Debarbieux S; Ammoury A; Lamant L; Paul C
    Ann Dermatol Venereol; 2010 Dec; 137(12):782-8. PubMed ID: 21134580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Good response of scleromyxedema and dermato-neuro syndrome to treatment with intravenous immunoglobulins].
    Bielsa I; Benvenutti F; Guinovart RM; Ferrándiz C
    Actas Dermosifiliogr; 2012 May; 103(4):317-20. PubMed ID: 21917233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients.
    Rongioletti F; Merlo G; Cinotti E; Fausti V; Cozzani E; Cribier B; Metze D; Calonje E; Kanitakis J; Kempf W; Stefanato CM; Marinho E; Parodi A
    J Am Acad Dermatol; 2013 Jul; 69(1):66-72. PubMed ID: 23453242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unusual granulomatous variant of scleromyxedema.
    Stetsenko GY; Vary JC; Olerud JE; Argenyi ZB
    J Am Acad Dermatol; 2008 Aug; 59(2):346-9. PubMed ID: 18485525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scleromyxedema, a positive effect with thalidomide.
    Jacob SE; Fien S; Kerdel FA
    Dermatology; 2006; 213(2):150-2. PubMed ID: 16902294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spontaneous resolution of facial papular mucinosis in a transplant patient.
    Braue A; Dolianitis C; Varigos G
    Australas J Dermatol; 2008 Aug; 49(3):164-6. PubMed ID: 18638226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scleromyxoedema.
    van Leersum F; Abdul Hamid M; Steijlen P
    Lancet; 2017 Apr; 389(10078):1549. PubMed ID: 27894593
    [No Abstract]   [Full Text] [Related]  

  • 17. End-stage disease of native kidneys in a patient with biopsy-proven Arndt-Gottron scleromyxoedema and recurrence in the transplanted kidney.
    Peeters P; Praet M; Van Vlem B; Naeyaert JM; Vanholder R
    Nephrol Dial Transplant; 2007 Oct; 22(10):3065-9. PubMed ID: 17616537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin.
    Rey JB; Luria RB
    J Am Acad Dermatol; 2009 Jun; 60(6):1037-41. PubMed ID: 19249127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of intravenous immunoglobulin in Arndt-Gottron scleromyxedema].
    Lopez L; Wierzbicka-Hainaut E; Villers A; Guillet G
    Ann Dermatol Venereol; 2009 Apr; 136(4):330-6. PubMed ID: 19361699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immunoglobulin therapy for scleromyxedema: a case report and review of literature.
    Sroa N; Campbell S; Bechtel M
    J Drugs Dermatol; 2010 Mar; 9(3):263-5. PubMed ID: 20232589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.